SARS-CoV-2: Unique Challenges of the Virus and Vaccines

References

• Bar-Zeev N, Moss WJ. 2020. Encouraging results from phase 1/2 COVID-19 vaccine trials. The Lancet. 396(10249):448–49.
   PubMed Web of Science ®Google Scholar
• Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M. 2011. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 85(23):12201–15.
   PubMed Web of Science ®Google Scholar
• Brian D, Baric R. 2005. Coronavirus genome structure and replication. Coronavirus Replication Reverse Genet. 287:1–30.
   Google Scholar
• Connors M, Giese NA, Kulkarni AB, Firestone C-Y, Morse HC, Murphy BR. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol. 68(8):5321–25.
   PubMed Web of Science ®Google Scholar
• Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang H-Y, Mitzner W. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 15(1):34–41.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC. 2021. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 184(9):2523.
   Web of Science ®Google Scholar
• Green MS, Abdullah R, Vered S, Nitzan D. 2021. A study of ethnic, gender and educational differences in attitudes toward COVID-19 vaccines in Israel - implications for vaccination implementation policies. Isr J Health Policy Res. 10(1):26.
   PubMed Web of Science ®Google Scholar
• Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, Setiawan AM, Rajamoorthy Y, Sofyan H, Mudatsir M. 2020. Acceptance of a COVID-19 vaccine in southeast Asia: a cross-sectional study in Indonesia. Front Public Health. 8:381.
   Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H. 2005. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 436(7047):112–16.
   PubMed Web of Science ®Google Scholar
• Jiang S. 2020. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. 579(7799):321–21.
   PubMed Web of Science ®Google Scholar
• Khoshkam Z, Aftabi Y, Stenvinkel P, Lawrence BP, Rezaei MH, Ichihara G, Fereidouni S. 2021. Recovery scenario and immunity in COVID-19 disease: a new strategy to predict the potential of reinfection. J Adv Res. 271–12. doi:10.1016/j.jare.2020.12.013
   Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 89(4):422–34.
   PubMed Web of Science ®Google Scholar
• Lambert P-H, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD. 2020. Consensus summary report for CEPI/BC March 12 –13,2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. 38(31):4783–91.
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. 2021. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 27(2):225–28.
   PubMed Web of Science ®Google Scholar
• Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. 2020. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 5(10):1185–91.
   PubMed Web of Science ®Google Scholar
• Li C, Zhu D, Zhao Y, Guo Q, Sun W, Li L, Gao D, Zhao P. 2020. Dendritic cells therapy with cytokine-induced killer cells and activated cytotoxic T Cells attenuated Th2 Bias immune response. Immunol Invest. 49(5):522–34.
   PubMed Web of Science ®Google Scholar
• Liu D, Liu J, Zeng S, Wang Y, Yuan Y, Xu S, Wang S, Yu R, Feng X, Li H, et al. 2020. Immunity-modulated sex disparity on COVID-19 prognosis. Clin Transl Med. 10(5):e164.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z. 2019. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 4(4):123–58.
   Web of Science ®Google Scholar
• Luo R, Delaunay‐Moisan A, Timmis K, Danchin A. 2021. SARS‐CoV‐2 biology and variants: anticipation of viral evolution and what needs to be done. Environ Microbiol. 23(3):1–25.
   PubMedGoogle Scholar
• Pereira F. 2021. SARS-CoV-2 variants lacking ORF8 occurred in farmed mink and pangolin. Gene. 784:784145596.
   Web of Science ®Google Scholar
• Qin X, Akter F, Qin L, Cheng J, Guo M, Yao S, Jian Z, Liu R, Wu S. 2020. Adaptive immunity regulation and cerebral ischemia. Front Immunol. 11:689. doi:10.3389/fimmu.2020.00689
   Google Scholar
• Randolph HE, Barreiro LB. 2020. Herd immunity: understanding COVID-19. Immunity. 52(5):737–41.
   PubMed Web of Science ®Google Scholar
• Sharma O, Sultan AA, Ding H, Triggle CR. 2020. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 11:112413.
   Web of Science ®Google Scholar
• Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, Zhuang Y, Tham CYL, Chia A, Smith GJD, et al. 2021. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34(6):108728.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. 2020. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 20(6):363–74.
   PubMed Web of Science ®Google Scholar
• Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. 2012. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS One. 7(4):e35421.
   PubMed Web of Science ®Google Scholar
• Van Riel D, De Wit E. 2020. Next-generation vaccine platforms for COVID-19. Nat Mater. 19(8):810–12.
   PubMed Web of Science ®Google Scholar
• Van Tassel K, Shachar C, Hoffman S. 2021. Covid-19 vaccine injuries—preventing inequities in compensation. N Engl J Med. 384(10):e34.
   PubMed Web of Science ®Google Scholar
• Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O’Toole Á. 2021. Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England. Nature. 593(7858):266–269. doi:10.1038/s41586-021-03470-x
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y. 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 323(11):1061–69.
   PubMed Web of Science ®Google Scholar
• Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, Liu X, Xie L, Li J, Ye J, et al. 2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 6:31. doi:10.1038/s41421-020-0168-9
   Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y. 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 180(7):934–43.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L. 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 8(4):420–22.
   PubMed Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A. 2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 369(6505):806–11.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang F, Yu W, He T, Yu J, Yi CE, Ba L, Li W, Farzan M, Chen Z. 2006. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol. 78(1):1–8.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J. 2020. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 71(16):2027–34.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, Li J-X, Yang B-F, Wang L, Wang W-J. 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 396(10249):479–88.
   PubMed Web of Science ®Google Scholar